S 42909

Drug Profile

S 42909

Alternative Names: S-42909

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Developer ILKOS THERAPEUTICS; Servier; Servier Canada
  • Class Antiulcers; Polyphenols; Small molecules
  • Mechanism of Action Matrix metalloproteinase 2 inhibitors; NADPH oxidase inhibitors; Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Leg ulcer
  • Phase I Wounds

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Leg ulcer (In adults, In the elderly) in Spain, Austria, Canada (PO) (NCT03077165) (EudraCT2016-004143-36)
  • 29 Dec 2016 Adverse events and pharmacodynamics data from a preclinical trial in Wound healing released by Institut de Recherches Internationales SERVIER
  • 26 Sep 2016 Ilkos Therapeutic plans a phase IIa trial for Leg ulcer (In adults, In elderly) in North America and Europe (PO) (NCT03077165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top